57,523 research outputs found
A Comparison of Moderate Oral Sedation Drug Regimens for Pediatric Dental Treatment: A Pilot Study
Purpose: Compare moderate oral sedation of pediatric patients using Hydroxyzine and Meperidine with either Diazepam or Midazolam in management of pediatric dental patients.
Methods: Randomized, double-blind, crossover pilot study of patients 3 to 7 years of age requiring two sedation visits. Frankl and Houpt behavior scores recorded at injection time, initiation of treatment and 100% oxygen at end of treatment. Postoperative phone call surveys conducted within eight hours and within 24 hours of discharge. Wilcoxon Signed-Rank tests, Fisher’s Exact Chi-squared test and 0.10 significance level.
Results: 25 subjects completed 35 sedations. Eight participants completed both treatments and demonstrated significantly higher total Houpt Scores with Diazepam at all treatment stages. Frankl scores favored Diazepam at injection time. More abnormal behavior was found with Midazolam, less memory of the visit with Diazepam, but longer sleep time with Diazepam.
Conclusions: Sedation with the Hydroxyzine, Meperidine and Diazepam regimen may allow for a better overall sedation experience. Postoperative monitoring is essential. The results are promising and demonstrate the value of a larger study on sedation with Diazepam
Comparison of Triple Combination Oral Sedation Regimens for Pediatric Dental Treatment
Purpose: Compare the efficacy of two benzodiazepines (diazepam or midazolam) in combination with meperidine and hydroxyzine for pediatric dental sedation. Methods: A randomized, double blind observation study of behaviors and outcomes related to two sedation groups. Frankl and Houpt behavior scores were recorded at three time points: injection time, initiation of treatment and at the end of treatment. Postoperative phone call surveys were conducted within eight hours of discharge to assess sleep, activity, and behavior. Results: A total of 40 sedation subjects were included in the study, of which 20 were treated with diazepam triple Combination (Di+M+H) and 20 with midazolam triple regime (Mi+M+H). Treatment was successful for 45% of cases with midazolam and 70% with diazepam (P value=.20). Houpt sleep scores were significantly higher for diazepam than midazolam at injection (P-value=.0043) and during treatment (P-value=.0152). Although Frankl scores, Houpt move and Houpt cry scores tended to favor diazepam, none were statistically significantly different. More abnormal behavior was reported with midazolam, though not statistically significant (35% vs 6%, P-value=.0854). Postoperative sleep time was longer for midazolam, but not significantly different (median sleep time: 61 vs 45 minutes, P-value=.2071). Conclusion: The diazepam, meperidine, hydroxyzine triple combination sedation regimen shows promising results as a successful alternative to midazolam triple combination. Longer postoperative monitoring may be required with diazepam, but this study has shown postoperative sleep times to be less than previously reported. Larger sample size is needed to determine if the current trend will be maintained
Enhanced GABAergic actions resulting from the coapplication of the steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam
Manual control analysis of drug effects on driving performance
The effects of secobarbital, diazepam, alcohol, and marihuana on car-driver transfer functions obtained using a driving simulator were studied. The first three substances, all CNS depressants, reduced gain, crossover frequency, and coherence which resulted in poorer tracking performance. Marihuana also impaired tracking performance but the only effect on the transfer function parameters was to reduce coherence
Recommended from our members
Trends in long-term prescribing of dependence forming medicines
Using patient-level primary care data to estimate the extent to which antidepressant medicines are prescribed to people continuously for long periods of time.
Aim
This descriptive research used patient-level primary care data to estimate the extent to which antidepressant medicines are prescribed to people continuously for long periods of time. The study also drew on survey data and data on the number of prescriptions dispensed.
Findings
- The number of antidepressant prescriptions dispensed each year in England doubled between 2008 and 2018
- Survey data show that the proportion of adults reporting use of antidepressants in the past year increased in the 1990s, and again between 2007 and 2014
- The average length of time that antidepressants are continuously prescribed to people for has increased over time.
- Some types of antidepressants (for example, tricyclics and other antidepressants) tend to be prescribed for longer periods than other types (such as SSRIs).
- In 2014, one in twelve prescribing periods for tricyclics and other antidepressants lasted for three years or more
Methods
The analyses in this report are descriptive and show the overall prevalence of long-term prescribing in each year.
We used a sample of around 50,000 patients prescribed at least one antidepressant medicine between 2000 and 2017. This was drawn from the Clinical Practice Research Datalink (CPRD). The CPRD contains data about prescriptions issued by GPs (including the length and size of prescription) and characteristics of the patients prescribed to (such as their age, sex, and area where they live). Medicines were grouped for analysis into: tricyclics, selective serotonin reuptake inhibitors (SSRIs), and other ADMs. The length of individual prescriptions and continuous prescribing periods were derived using information on consultation dates, the quantity of tablets prescribed, and the numeric daily dose
Treatments for spasticity and pain in multiple sclerosis: a systematic review
Objectives:
To identify the drug treatments currently
available for the management of spasticity and pain in
multiple sclerosis (MS), and to evaluate their clinical and
cost-effectiveness.
Data sources:
Electronic bibliographic databases,
National Research Register, MRC Clinical Trials Register
and the US National Institutes of Health Clinical Trials
Register.
Review methods:
Systematic searches identified 15
interventions for the treatment of spasticity and 15
interventions for treatment of pain. The quality and
outcomes of the studies were evaluated. Reviews of
the treatment of spasticity and pain when due to other
aetiologies were also sought.
Results:
There is limited evidence of the effectiveness
of four oral drugs for spasticity: baclofen, dantrolene,
diazepam and tizanidine. Tizanidine appears to be no
more effective than comparator drugs such as baclofen
and has a slightly different side-effects profile. Despite
claims that it causes less muscle weakness, there was
very little evidence that tizanidine performed any
better in this respect than other drugs, although it is
more expensive. The findings of this review are
consistent with reviews of the same treatments for
spasticity derived from other aetiologies. There is good
evidence that both botulinum toxin (BT) and intrathecal
baclofen are effective in reducing spasticity, and both
are associated with functional benefit. However, they
are invasive, and substantially more expensive. None of
the studies included in the review of pain were
designed specifically to evaluate the alleviation of pain
in patients with MS and there was no consistency
regarding the use of validated outcome measures. It
was suggested that, although expensive, the use of
intrathecal baclofen may be associated with significant
savings in hospitalisation costs in relation to bed-bound
patients who are at risk of developing pressure sores,
thus enhancing its cost-effectiveness. No studies of
cost-effectiveness were identified in the review
of pain. There is evidence, albeit limited, of the
clinical effectiveness of baclofen, dantrolene,
diazepam, tizanidine, intrathecal baclofen and BT
and of the potential cost-effectiveness of intrathecal
baclofen in the treatment of spasticity
in MS.
Conclusions:
Many of the interventions identified are
not licensed for the alleviation of pain or spasticity in
MS and the lack of evidence relating to their
effectiveness may also limit their widespread use.
Indeed, forthcoming information relating to the use of
cannabinoids in MS may result in there being better
evidence of the effectiveness of new treatments than of
any of the currently used drugs. It may therefore be of
value to carry out double-blind randomised controlled
trials of interventions used in current practice, where
outcomes could include functional benefit and impact
on quality of life. Further research into the
development and validation of outcomes measures for
pain and spasticity may also be useful, as perhaps would
cost–utility studies
Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series.
IntroductionIn treating refractory epilepsy, many clinicians are interested in methods used to transition patients receiving clonazepam to clobazam to maintain or increase seizure control, improve tolerability of patients' overall drug therapy regimens, and to enhance quality of life for patients and their families. However, no published guidelines assist clinicians in successfully accomplishing this change safely.Case presentationsThe following three case reports provide insight into the transition from clonazepam to clobazam. First, an 8-year-old Caucasian boy with cryptogenic Lennox-Gastaut syndrome beginning at 3.5 years of age, who was experiencing multiple daily generalized tonic-clonic, absence, myoclonic, and tonic seizures at presentation. Second, a 25-year-old, left-handed, White Hispanic man with moderate mental retardation and medically refractory seizures that he began experiencing at 1 year of age, secondary to tuberous sclerosis. When first presented to an epilepsy center, he had been receiving levetiracetam, valproate, and clonazepam, but reported having ongoing and frequent seizures. Third, a 69-year-old Korean woman who had been healthy until she had a stroke in 2009 with subsequent right hemiparesis; as a result, she became less physically and socially active, and had her first convulsive seizure approximately 4 months after the stroke.ConclusionsFrom these cases, we observe that a rough estimate of final clobazam dosage for each mg of clonazepam under substitution is likely to be at least 10-fold, probably closer to 15-fold for many patients, and as high as 20-fold for a few. Consideration and discussion of the pharmacokinetic, pharmacologic, and clinical properties of 1,4- and 1,5-benzodiazepine action provide a rationale on why and how these transitions were successful
Raja Bandung Banana (Musa ParadisiacaL.cv Raja Bandung) Prevents Increased Systolic Blood Pressure in Rats Given Acute Stress Test
The relationships between stress and hypertension have been evaluated. Heightened blood pressure (BP) reactions to acute stress have been implicated in cardiovascular disease\u27s development. Consumption of fruit or vegetables lowering BP. This study aimed to evaluate the effect of Raja Bandung Banana (Musa paradisiacaL. cv Raja Bandung) on blood pressure after acute restraint stress and forced swim test.Twenty male Sprague dawley rats were divided into 4 groups (A,B,C,D) and adapted for 3 days. At 4th day, groups were administered 2 g/200gBw AIN-93M, then exposed to acute restraint (1hour), except group A. After restraint, A&B received water, C received diazepam 0,5mg/kgBW, and D received banana 2,52 g/200gBW. One hour later, the forced swim test was carried out (45 minutes). Blood pressure was measured 1 hour after swim. Result showed,mean of blood pressure significantly increased after treatment (p<0,01) all groups. But, the increasing of blood pressure in C and D group was lower than unrestraint (A) and control (B) group. There was significant difference of blood pressure between control (A&B) and intervention group (C&D), but no significant difference between C and D. Thisresults indicate that Raja Bandung Banana can prevent increased blood pressure on acute stress condition as effective as diazepam
Pharmacodynamic and pharmacokinetic effects of flumazenil and theophylline application in rats acutely intoxicated by diazepam
Background/Aim. The majority of symptoms and signs of acute diazepam poisoning are the consequence of its sedative effect on the CNS affecting selectively polisynaptic routes by stimulating inhibitory action of GABA. The aim of the present study was to examine the effects of combined application of theophylline and flumazenil on sedation and impaired motor function activity in acute diazepam poisoning in rats. Methods. Male Wistar rats were divided in four main groups and treated as follows: group I - with increasing doses of diazepam in order to produce the highest level of sedation and motor activity impairment; group II - diazepam + different doses of flumazenil; group III - diazepam + different doses of theophylline; group IV - diazepam + combined application of theophylline and flumazenil. Concentrations of diazepam and its metabolites were measured with LC-MS. The experiment was performed on a commercial apparatus for spontaneous motor-activity registration (LKBFarad, Sweden). Assessment of diazepam- induced neurotoxic effects and effects after theophylline and flumazenil application was performed with rotarod test on a commercial apparatus (Automatic treadmill for rats, Ugo Basile, Italy). Results. Diazepam in doses of 10 mg/kg and 15 mg/kg produced long-time and reproducible pharmacodynamic effects. Single application of flumazenil or theophylline antagonized effects of diazepam, but not completely. Combined application of flumazenile and theophylline resulted in best effects on diazepaminduced impairment of motoric activity and sedation. As a result of theopylline application there was better elimination of diazepam and its metabolites. Conclusion. Combined application of flumazenil and theophylline resulted in the best antidotal effects in the treatment of diazepam poisoned rats. These effects are a result of different mechanisms of their action, longer half-life of theophylline in relation to that of flumezenil and presumably the diuretic effect of theophylline
Using a new high-throughput video-tracking platform to assess behavioural changes in Daphnia magna exposed to neuro-active drugs
© 2019. ElsevierOne of the major challenges that faces today regulatory risk assessment is to speed up the way of assessing threshold sublethal detrimental effects of existing and new chemical products. Recently advances in imaging allows to monitor in real time the behaviour of individuals under a given stress. Light is a common stress for many different organisms. Fish larvae and many invertebrate species respond to light altering their behaviour. The water flea Daphnia magna as many other zooplanktonic species has a marked diel vertical phototactic swimming behaviour against light due to fish predation. The aim of this study was to develop a high throughput image analysis to study changes in the vertical swimming behaviour to light of D. magna first reproductive adult females exposed to 0.1 and 1 µg/L of four psychiatric drugs: diazepam, fluoxetine, propranolol and carbamazepine during their entire life. Experiments were conducted using a new custom designed vertical oriented four 50 mL chamber device controlled by the Noldus software (Netherlands). Changes in speed, preferred area (bottom vs upper areas) and animal aggregation were analysed using groups of animals under consecutive periods of dark and apical light stimulus of different intensities. Obtained results indicated that light intensity increased the speed but low light intensities allowed to better discriminate individual responses to the studied drugs. The four tested drugs decreased the response of exposed organisms to light: individuals move less, were closer to the bottom and at low light intensities were closer each other. At high light intensities, however, exposed individuals were less aggregated. Propranolol, carbamazepine and fluoxetine were the compounds effecting most the behaviour. Our results indicated that psychiatric drugs at environmental relevant concentrations alter the vertical phototactic behaviour of D. magna individuals and that it is possible to develop appropriate high-throughput image analysis devices to measure those responses.Peer ReviewedPostprint (author's final draft
- …
